Jean-Paul Wuerth

Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy

W. Kline Bolton, Daniel C. Cattran, Mark E. Williams et al. · American Journal of Nephrology · 2004 · 448 citations

Design and Baseline Characteristics for the Aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II)

B. I. Freedman, Jean-Paul Wuerth, Kenneth Cartwright et al. · Controlled Clinical Trials · 1999 · 250 citations

Diabetes Management, Renal Function, Renal Disease +10

Analysis of the HNF4α gene in Caucasian Type II diabetic nephropathic patients

Jennifer A. Price, Sallyanne C. Fossey, Michèle M. Sale et al. · Diabetologia · 2000 · 38 citations · Full text

Urology, Diabetes Epidemiology, Renal Function +9

Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity

Achim C. Mellinghoff, Armin J. Reininger, Jean-Paul Wuerth et al. · Diabetic Medicine · 1997 · 24 citations

Type 1, Plasma-age Levels, Biochemistry +15

Divergent dimerization properties of mutant beta 1 thyroid hormone receptors are associated with different dominant negative activities.

Enhui Hao, J B Menke, Andrew Smith et al. · Molecular Endocrinology · 1994 · 24 citations · Full text